Angiotensin-(1-7)
Evidence: CCardiovascular / Vascular
Evidence Snapshot
Regulatory Context
This page summarizes research on the peptide and does not imply that the peptide is an FDA-approved drug or approved for a particular indication. Molecule-specific regulatory status requires verification against official regulatory records.
Research Takeaway
Angiotensin-(1-7) is a distinct seven-residue angiotensin-system peptide and must not be merged with Angiotensin I/II/III/IV/(1-9), Alamandine, ACE2, the Mas receptor, or Angiotensin-IV-derived compounds such as Dihexa.
Evidence boundary: ACE2/Mas pathway biology does not by itself establish outcomes from administering Angiotensin-(1-7).
See all 6 evidence claims →Quick Summary
Angiotensin-(1-7) is a distinct seven-residue peptide in the renin-angiotensin system. It has direct human vascular and randomized clinical-trial evidence, but the human pharmacology is not uniformly concordant and a large TXA-127 COVID trial stopped early for low probability of efficacy, supporting a cautious Grade C interpretation rather than pathway-based therapeutic claims.
Mechanism & Research Overview
Angiotensin-(1-7) is a distinct seven-residue peptide in the renin-angiotensin system. It has direct human vascular and randomized clinical-trial evidence, but the human pharmacology is not uniformly concordant and a large TXA-127 COVID trial stopped early for low probability of efficacy, supporting a cautious Grade C interpretation rather than pathway-based therapeutic claims.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Angiotensin-(1-7) is a distinct seven-residue angiotensin-system peptide and must not be merged with Angiotensin I/II/III/IV/(1-9), Alamandine, ACE2, the Mas receptor, or Angiotensin-IV-derived compounds such as Dihexa.
Does not establish
Evidence boundary: ACE2/Mas pathway biology does not by itself establish outcomes from administering Angiotensin-(1-7).
Sources: Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man; Angiotensin-(1-7)-induced renal vasodilation in hypertensive humans is attenuated by low sodium intake and angiotensin II co-infusion
Supported
Exact Angiotensin-(1-7) has been administered directly to humans in controlled vascular studies, where measurable regional vasodilator interactions and renal vascular effects have been reported.
Does not establish
Evidence boundary: Human vascular studies are mixed and largely regional/physiologic rather than long-term treatment trials.
Sources: Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man; Angiotensin-(1-7) does not affect vasodilator or TPA responses to bradykinin in human forearm; Angiotensin-(1-7)-induced renal vasodilation in hypertensive humans is attenuated by low sodium intake and angiotensin II co-infusion
Supported
Two early human forearm studies reached different conclusions about whether Angiotensin-(1-7) potentiates bradykinin responses.
Does not establish
Evidence boundary: The conflicting results argue against presenting this mechanism as uniformly established in humans.
Sources: Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man; Angiotensin-(1-7) does not affect vasodilator or TPA responses to bradykinin in human forearm
Supported
Synthetic Angiotensin-(1-7) (TXA-127) has been tested in randomized clinical trials in severe/hypoxemic COVID-19, including a larger multicenter trial that stopped early for low probability of efficacy on its primary endpoint.
Does not establish
Evidence boundary: These disease-specific trials do not establish Angiotensin-(1-7) as a broadly effective cardiovascular therapy; the largest frozen trial was negative/futile for its primary efficacy objective.
Sources: A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1-7 (TXA-127) for the treatment of severe COVID-19; Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials; Angiotensin-(1-7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1-2 randomized clinical trial
Supported
Randomized clinical studies provide short-term human safety/tolerability data for synthetic Angiotensin-(1-7), but not a broad long-term safety profile across indications.
Sources: A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1-7 (TXA-127) for the treatment of severe COVID-19; Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials; Angiotensin-(1-7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1-2 randomized clinical trial
Supported
No molecule-specific regulatory conclusion is frozen for Angiotensin-(1-7) in Stage 2A.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Ang-(1-7) is vasoactive; hemodynamic effects and interaction with the broader renin-angiotensin system are biologically relevant safety considerations.Safety Consideration
Human vascular studies are not fully concordant.Safety Consideration
Large disease-specific randomized evidence does not establish broad therapeutic efficacy.
Research Areas Being Studied
Research areas discussed on this page reflect the Cardiovascular / Vascular category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Angiotensin-(1-7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1-2 randomized clinical trial (2024):
- Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials (2023):
- A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1-7 (TXA-127) for the treatment of severe COVID-19 (2022):
- Angiotensin-(1-7)-induced renal vasodilation in hypertensive humans is attenuated by low sodium intake and angiotensin II co-infusion (2013):
- Angiotensin-(1-7) does not affect vasodilator or TPA responses to bradykinin in human forearm (2001):
- Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man (2001):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Angiotensin-(1-7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1-2 randomized clinical trial | 2024 | ICU COVID-19 patients; phase 1-2 randomized clinical trial | Tested short-term continuous IV Ang-(1-7) for safety and efficacy in ICU COVID-19 patients. | ||
| Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials | 2023 | Hospitalized hypoxemic adults with COVID-19; multicenter randomized trial; TXA-127 n=343 total randomized | The TXA-127 trial met prespecified early-stopping criteria for low probability of efficacy on oxygen-free days. | ||
| A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1-7 (TXA-127) for the treatment of severe COVID-19 | 2022 | Severe COVID-19 patients; randomized placebo-controlled pilot | Pilot therapeutic study directly tested synthetic Ang-(1-7) in severe COVID-19. | ||
| Angiotensin-(1-7)-induced renal vasodilation in hypertensive humans is attenuated by low sodium intake and angiotensin II co-infusion | 2013 | 57 hypertensive patients undergoing renal angiography; randomized sodium conditions and Ang II co-infusion subgroup | Intrarenal Ang-(1-7) produced renal vasodilation under sodium-rich conditions; effect was attenuated by sodium restriction and/or Ang II co-infusion. | ||
| Angiotensin-(1-7) does not affect vasodilator or TPA responses to bradykinin in human forearm | 2001 | Eight normotensive subjects; graded brachial-artery Ang-(1-7) | This human forearm study did not confirm potentiation of bradykinin vasodilator or tPA responses. | ||
| Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man | 2001 | Normotensive healthy men; placebo-controlled double-blind crossover; intra-arterial peptide infusion | Ang-(1-7) potentiated bradykinin vasodilation in human forearm resistance vessels. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
No Regulatory Documents & Official Trial Registries Listed Yet
This section will be updated as sources are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-08-25.
Follow research updates for Angiotensin-(1-7)
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.